THRD | Third Harmonic Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	11.30 - 12.15
52 Week Range	5.73 - 16.94
Beta	4.44
Implied Volatility	398.44%
IV Rank	35.14%
Day's Volume	81,893
Average Volume	81,037
Shares Outstanding	41,097,510
Market Cap	493,170,120
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-09-14

Valuation
Profitability
Growth
Health
P/E Ratio	-14.81
Forward P/E Ratio	N/A
EPS	-0.81
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	31
Country	USA
Website	THRD

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.

THRD's peers: EDSA, HOWL, PCSA, RLMD, RLYB, SABS, SYBX, TNGX, TRDA, TTNP, VALN, VERA, VIGL, XOMA, QNCX, SNSE, NXTC, NUVB, GRPH, MACK, CGEM, EWTX, GLUE, PMVP, ENOB, RVMD, PASG, ACRV, ELYM, PROK

*Chart delayed

Analyzing fundamentals for THRD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see THRD Fundamentals page.

Watching at THRD technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on THRD Technicals page.